Dimensional Fund Advisors LP decreased its stake in Cambrex Corp. (NYSE:CBM) by 7.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,359,839 shares of the company’s stock after selling 116,709 shares during the period. Dimensional Fund Advisors LP owned approximately 4.23% of Cambrex Corp. worth $70,344,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Bayesian Capital Management LP purchased a new stake in Cambrex Corp. during the first quarter valued at $276,000. Loomis Sayles & Co. L P boosted its stake in Cambrex Corp. by 6.1% in the first quarter. Loomis Sayles & Co. L P now owns 428,046 shares of the company’s stock valued at $18,834,000 after buying an additional 24,763 shares during the period. Third Avenue Management LLC purchased a new stake in Cambrex Corp. during the first quarter valued at $3,374,000. Royce & Associates LP boosted its stake in Cambrex Corp. by 0.9% in the first quarter. Royce & Associates LP now owns 203,298 shares of the company’s stock valued at $8,945,000 after buying an additional 1,798 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in Cambrex Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 812,239 shares of the company’s stock valued at $35,739,000 after buying an additional 2,588 shares during the period. Institutional investors own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) traded down 1.19% during midday trading on Thursday, reaching $45.00. 110,867 shares of the company’s stock were exchanged. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 22.75 and a beta of 1.45. Cambrex Corp. has a 12-month low of $29.50 and a 12-month high of $59.41. The firm has a 50-day moving average price of $45.21 and a 200 day moving average price of $47.68.
Cambrex Corp. (NYSE:CBM) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.09. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. The business earned $118.22 million during the quarter, compared to analysts’ expectations of $114.85 million. During the same quarter in the previous year, the company earned $0.63 EPS. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, analysts expect that Cambrex Corp. will post $2.56 EPS for the current fiscal year.
Separately, Zacks Investment Research cut shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th.
In other news, Director William B. Korb sold 3,420 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $55.00, for a total value of $188,100.00. Following the completion of the sale, the director now directly owns 23,982 shares in the company, valued at approximately $1,319,010. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.63% of the stock is currently owned by company insiders.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.